	US 12,084,484 B2
	Interleukin-2 agents and uses thereof
Scott Moore Carlson, Boston, MA (US); Gregory Babcock, Marlborough, MA (US); Zachary Shriver, Winchester, MA (US); and Boopathy Ramakrishnan, Braintree, MA (US)
Assigned to Visterra, Inc., Waltham, MA (US)
Filed by VISTERRA, INC., Waltham, MA (US)
Filed on Jul. 24, 2020, as Appl. No. 16/937,993.
Claims priority of provisional application 62/983,061, filed on Feb. 28, 2020.
Claims priority of provisional application 62/879,137, filed on Jul. 26, 2019.
Prior Publication US 2021/0024601 A1, Jan. 28, 2021
Int. Cl. C07K 14/55 (2006.01); A61P 13/12 (2006.01); C07K 16/24 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/55 (2013.01) [A61P 13/12 (2018.01); C07K 16/246 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/31 (2013.01)]

23 Claims

1. An interleukin-2 (IL-2) variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1031 and

(i) an amino acid substitution H16L, H16N, or I92S, and (ii) amino acid substitutions V69A, Q74P, and C125S.